U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18N8O5.H2O
Molecular Weight 408.3699
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of REGADENOSON

SMILES

CN=C(c1cnn(c1)-c2nc(c3c(n2)n(cn3)[C@@]4([H])[C@@]([H])([C@@]([H])([C@@]([H])(CO)O4)O)O)N)O.O

InChI

InChIKey=CDQVVPUXSPZONN-WPPLYIOHSA-N
InChI=1S/C15H18N8O5.H2O/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14;/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21);1H2/t7-,9-,10-,14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H18N8O5
Molecular Weight 390.3546
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html

Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
LEXISCAN

Approved Use

Lexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress (1).

Launch Date

1.20778562E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.6 ng/mL
400 μg single, intravenous
dose: 400 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
REGADENOSON plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.7 ng × h/mL
400 μg single, intravenous
dose: 400 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
REGADENOSON plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
400 μg single, intravenous
dose: 400 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
REGADENOSON plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (3 patients)
Flushing (3 patients)
Shortness of breath (4 patients)
Nausea and vomiting (5 patients)
Change in ECG (1 patient)
Headache (4 patients)
Sources: Page: 1211
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (3 patients)
Dizziness (3 patients)
Shortness of breath (1 patient)
Nausea and vomiting (2 patients)
Headache (3 patients)
Sources: Page: 1211
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Palpitation, Dizziness...
Other AEs:
Palpitation (4 patients)
Dizziness (2 patients)
Flushing (4 patients)
Shortness of breath (2 patients)
Change in ECG (1 patient)
Headache (1 patient)
Sources: Page: 1211
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (2 patients)
Palpitation (2 patients)
Dizziness (3 patients)
Flushing (1 patient)
Nausea and vomiting (4 patients)
Headache (3 patients)
Sources: Page: 1211
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (4 patients)
Dizziness (3 patients)
Flushing (8 patients)
Shortness of breath (3 patients)
Nausea and vomiting (3 patients)
Change in ECG (7 patients)
Headache (7 patients)
Sources: Page: 1211
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Palpitation, Dizziness...
Other AEs:
Palpitation (2 patients)
Dizziness (1 patient)
Flushing (1 patient)
Change in ECG (3 patients)
Sources: Page: 1211
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (2 patients)
Dizziness (1 patient)
Flushing (3 patients)
Shortness of breath (1 patient)
Change in ECG (1 patient)
Sources: Page: 1211
AEs

AEs

AESignificanceDosePopulation
Change in ECG 1 patient
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 3 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 3 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 4 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 4 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 5 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 2 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 3 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 3 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 3 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 2 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 2 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 4 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 4 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 1 patient
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 2 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 2 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 4 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 4 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 7 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 7 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 8 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 2 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 3 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 2 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 3 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Adenosine receptors as therapeutic targets.
2006 Mar
Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.
2007 Jul
New stress test agents reduce adverse effects.
2008 May 14
Selective adenosine agonists and myocardial perfusion imaging.
2012 Feb
Patents

Sample Use Guides

In Vivo Use Guide
5 mL (0.4 mg) by rapid injection; followed immediately by saline flush and radiopharmaceutical.
Route of Administration: Intravenous
10 nM CVT-3146 decreased coronary perfusion pressure by 23 mm Hg in rat isolated perfused heart.
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:08:21 UTC 2021
Edited
by admin
on Sat Jun 26 15:08:21 UTC 2021
Record UNII
2XLN4Y044H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
REGADENOSON
DASH   EMA EPAR   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
REGADENOSON MONOHYDRATE [MI]
Common Name English
RAPISCAN
Brand Name English
REGADENOSON [VANDF]
Common Name English
REGADENOSON MONOHYDRATE [MART.]
Common Name English
REGADENOSON [WHO-DD]
Common Name English
REGADENOSON MONOHYDRATE
MART.   MI  
Common Name English
REGADENOSON [USAN]
Common Name English
REGADENOSON [ORANGE BOOK]
Common Name English
ADENOSINE, 2-(4-((METHYLAMINO)CARBONYL)-1H-PYRAZOL-1-YL)-, MONOHYDRATE
Systematic Name English
LEXISCAN
Brand Name English
REGADENOSON [EMA EPAR]
Common Name English
1-(6-AMINO-9-.BETA.-D-RIBOFURANOSYL-9H-PURIN-2-YL)-N-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE, MONOHYDRATE
Common Name English
CVT-3146
Code English
Classification Tree Code System Code
NDF-RT N0000175788
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
WHO-ATC C01EB21
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
EMA ASSESSMENT REPORTS RAPISCAN (AUTHORIZED: MYOCARDIAL PERFUSION IMAGING)
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
WHO-VATC QC01EB21
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
NDF-RT N0000178375
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL317052
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
IUPHAR
5596
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
MESH
C430916
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
LACTMED
Regadenoson
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
DRUG BANK
DB06213
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
MERCK INDEX
M9517
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY Merck Index
EPA CompTox
875148-45-1
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
PUBCHEM
44154280
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
DRUG CENTRAL
2362
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
CAS
875148-45-1
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
RXCUI
640062
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
REGADENOSON
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
FDA UNII
2XLN4Y044H
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
NCI_THESAURUS
C74420
Created by admin on Sat Jun 26 15:08:21 UTC 2021 , Edited by admin on Sat Jun 26 15:08:21 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY